Business Wire | Sep 8, 2020 07:30AM EDT

Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences

Sep. 08, 2020

DURHAM, N.C.--(BUSINESS WIRE)--Sep. 08, 2020--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that the Company will participate in the following virtual investor conferences in September.

* Citi 15th Annual BioPharma Conference Date: Thursday, September 10, 2020 Time: 9:50 a.m. Eastern Time Panel Discussion: Ophthalmology - Seeing 20/20 in 2020 Panelist: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer

* H.C. Wainwright 22nd Annual Global Investment Conference Date: Tuesday, September 15, 2020 Time: 1:30 p.m. Eastern Time Presenter: Richard J. Rubino, Chief Financial Officer Presentation Type: Fireside

* Cantor Global Healthcare Conference Date: Wednesday, September 16, 2020 Time: 10:40 a.m. Eastern Time Presenter: Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer Presentation Type: Fireside

The panel and fireside discussions will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com. A replay of the webcast will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa(r) (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa(r), the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa(r), including the product label, is available at www.rhopressa.com. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan(r) (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa(r) and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan(r), the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan(r), including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005025/en/

CONTACT: Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com

CONTACT: Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com